LexBio Therapeutics
LexBio (朗睿) is an AI-driven drug discovery company based in Suzhou Industrial Park, China. They leverage advanced AI algorithms and computer technology, combined with extensive international pharmaceutical experience, to accelerate the development of First-in-Class (FIC) and Best-in-Class (BIC) innovative drugs. The company's core strategy focuses on AI-powered analysis, evaluation, and screening of novel drug targets using professional databases and deep learning. This approach aims to rapidly identify and optimize drug candidates, significantly reducing trial-and-error costs in target validation and molecular construction, and shortening the overall drug R&D process through informatization and iteration. LexBio's business model includes independent R&D, project collaborations, and technology transfers. Their technology platform integrates machine learning into target discovery, virtual screening, and targeted drug molecule generation, utilizing various deep neural networks to achieve goal-oriented multi-modal functions. They have developed proprietary technologies and platforms such as LexMolDB, LexBAP, LexMolProp, LexGen3D, LexFilter, and LexOPT. LexBio's mission is to overcome challenging diseases and benefit global patients by developing drugs that address clinical drug resistance and toxic side effects, aiming for first-in-class and best-in-class therapeutics.
LexBio Therapeutics
LexBio (朗睿) is an AI-driven drug discovery company based in Suzhou Industrial Park, China. They leverage advanced AI algorithms and computer technology, combined with extensive international pharmaceutical experience, to accelerate the development of First-in-Class (FIC) and Best-in-Class (BIC) innovative drugs. The company's core strategy focuses on AI-powered analysis, evaluation, and screening of novel drug targets using professional databases and deep learning. This approach aims to rapidly identify and optimize drug candidates, significantly reducing trial-and-error costs in target validation and molecular construction, and shortening the overall drug R&D process through informatization and iteration. LexBio's business model includes independent R&D, project collaborations, and technology transfers. Their technology platform integrates machine learning into target discovery, virtual screening, and targeted drug molecule generation, utilizing various deep neural networks to achieve goal-oriented multi-modal functions. They have developed proprietary technologies and platforms such as LexMolDB, LexBAP, LexMolProp, LexGen3D, LexFilter, and LexOPT. LexBio's mission is to overcome challenging diseases and benefit global patients by developing drugs that address clinical drug resistance and toxic side effects, aiming for first-in-class and best-in-class therapeutics.